Is Xilio Development Inc (XLO) overvalued? · rev $19.1M
Xilio Development Inc (XLO) is a biotechnology company listed on NASDAQ.
This page asks whether Xilio Development Inc (XLO) looks expensive on cached numbers — not a short thesis.
Latest reported XLO revenue for 2025-09-30 was $19.1M. Net income was -$45.4M. XLO currently screens at market cap $55.3M.
XLO currently screens at market cap $55.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next XLO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the XLO stock page for the full model, not this heading.
Not investment advice.